Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3050 Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis

Introduction: Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clift A

Authors: Clift A, Frilling A, Braat A, Alsafi A, Wasan H,

Keywords: liver, metastases, radioembolization, yttrium, selective internal radiation therapy,

#2997 Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden

Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wadsley J, Shah T,

Keywords: 177Lu-DOTATATE, metastases, quality of life,

#2889 Transcatheter Arterial Embolization (TAE) of NEN Metastases: Efficacy and Predictors of Response

Introduction: Transcatheter-Arterial embolization (TAE) is an established regional, palliative treatment option for liver metastases in patients (pts) with neuroendocrine neoplasms (NENs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Rowland S, Armeni E, Sullivan L, Aristidou I, Gopaul A,

Keywords: NEN, TAE, metastatic liver burden,

#2881 Patient-Derived Tumor Xenograft Combined with Chemotherapy Drug Sensitivity Test in a Patient with Pancreatic Neuroendocrine Carcinoma

Introduction: Pancreatic neuroendocrine carcinoma (p-NEC) with liver metastasis has a poor prognosis. The treatment is mainly chemotherapy which is now still a huge challenge on NEC with high ki-67 index.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Bai J

Authors: Bai J, Tang Q,

Keywords: Pancreatic neuroendocrine carcinoma, chemotherapy, Doxorubicin+mitomycin+loplatin, patient-derived tumor xenograft, Carbon ion,

#2835 Primary Hepatic Neuroendocrine Carcinoma: Case Report and Literature Review

Introduction: Primary hepatic neuroendocrine carcinoma (PHNEC) is an extremely rare neuroendocrine carcinoma (NEC) that originate from the liver. The diagnosis of PHNEC remains challenging because of its rarity, and its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Saidi M, Ghomari S,

Keywords: primary hepatic neuroendocrine carcinoma, liver biopsy, immunohistochemical staining, Somatostatin analogue,